MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Ataxia: Treatment"

  • 2022 International Congress

    Therapies, Research Funding and Racial Diversity in Cerebellar Ataxia: A Systematic Review of the Literature

    C. Kingsbury, S. Ghanekar, Y. Huang, T. Ashizawa, S. Kuo, C. Gooch, T. Zesiewicz (Tampa, USA)

    Objective: To understand the scope of clinical research in cerebellar ataxia by performing a systematic review of controlled clinical trials over the past 50 years,…
  • 2022 International Congress

    Isolated ZIC4 antibody associated paraneoplastic cerebellar degeneration

    A. Agarwal, A. Garg, A. Srivastava (New Delhi, India)

    Objective: Anti-ZIC4 antibodies have recently been associated with paraneoplastic cerebellar degeneration (PCD) and are usually associated with small cell carcinoma lung. However, most of the…
  • 2022 International Congress

    Gene Expression Quantification to Assess Frataxin Replacement Therapies in Friedreich’s Ataxia

    M. Baile, D. Schecter, A. Miller, T. Galas, N. Scherer, R. Chen, N. Ruiz, D. Bettoun (Philadelphia, USA)

    Objective: To identify genetic disease and efficacy markers for Friedreich’s ataxia (FRDA) Background: FRDA is a genetic disease caused by decreased expression of the mitochondrial…
  • 2022 International Congress

    Leading Therapeutic Molecules Target Transcription Factors Binding to Repressor Region in FXN Gene

    V. Swarup, H. Singh, D. Gupta, I. Singh, A. Srivastava (New Delhi, India)

    Objective: To investigate interactions of transcription factors (TFs) binding to repressor region located upstream to FXN gene with leading therapeutic molecules. Background: Low levels of…
  • 2022 International Congress

    Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia

    D. Bettoun, T. Galas, D. Schecter, N. Ruiz, R. Clayton, J. Farmer (Bala Cynwyd, USA)

    Objective: To evaluate the pharmacodynamic (PD) and safety profiles of subcutaneous (SC) administration of multiple ascending doses of CTI-1601 in patients age ≥18 years with…
  • MDS Virtual Congress 2021

    Cerebellar bioenergetic depletion following ubiquinol supplementation in a patient with COQ8A-related ataxia

    J. Prasuhn, M. Göttlich, B. Ebeling, C. Bodemann, S. Großer, I. Wellach, K. Reuther, H. Hanssen, N. Brüggemann (Lübeck, Germany)

    Objective: To non-invasively map the individual treatment response in a patient with COQ8A-related ataxia following coenzyme Q10 supplementation. Background: Primary coenzyme Q10 (CoQ10) deficiency is…
  • MDS Virtual Congress 2020

    The use of Virtual Reality to Assess the Quality of Life in Patients with Spinocerebellar Ataxia

    B. Zeigelboim, B. Cavalcante-Leao, J.M Malisky, G.S Santos, M.S Severiani, H.T Teive (Curitiba, Brazil)

    Objective: To assess independence, confidence and balance for  development daily activities in patients with SCAs, before and after rehabilitation with virtual reality (ViR). Background: Spinocerebellar…
  • MDS Virtual Congress 2020

    Balance rehabilitation with a virtual reality protocol for patients with hereditary spastic paraplegia: Protocol for a clinical trial

    B. Zeigelboim, G. Santos, M.I Severiano, H. Teive, B. Cavalcante-Leao (Curitiba, Brazil)

    Objective: Determine  benefits of vestibular rehabilitation involving virtual reality through the comparison of pre-intervention and post-intervention evaluations in individuals with hereditary spastic paraplegia. Background: Neurodegenerative…
  • MDS Virtual Congress 2020

    Beyond Parkinson’s disease: the use of standardized speech, physical and occupational therapies for PD in atypical parkinsonisms, other movement disorders and aging conditions

    C. Fox, L. Guse, A. Halpern (Tucson, AZ, USA)

    Objective: 1) Examine how speech, physical and occupational therapists are using evidence-based, Parkinson’s specific treatments (LSVT LOUD and LSVT BIG) in atypical parkinsonisms, other movement…
  • MDS Virtual Congress 2020

    Implementation of computer game technologies for patients with ataxia due to post-traumatic head injury: Randomized controlled trial

    T. Voloshyn, V. Kozyavkin, O. Kachmar (Truskavets, Ukraine)

    Objective: Up to 85 % of patients with post-traumatic brain injury suffer motor discoordination, ataxia and dyspraxia. The formation of the correct movement patterns, improved…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley